1. [CASE 1 — QUESTION 1] A 74-year-old woman with hypertension treated with hydrochlorothiazide (HCTZ) 25 mg daily for four years presents to the emergency department with two days of confusion, lethargy, and anorexia following an episode of nausea and vomiting from a community-acquired urinary tract infection. Her daughter notes she has seemed increasingly disoriented since the illness began. On examination her blood pressure is 138/84 mmHg, heart rate 82 bpm, and she is mildly confused, scoring 22/30 on a brief cognitive screen. Serum sodium is 112 mEq/L, serum osmolality 234 mOsm/kg, serum potassium 3.6 mEq/L, and creatinine 1.0 mg/dL (baseline). Urine osmolality is 648 mOsm/kg and urine sodium is 38 mEq/L. Which of the following best explains the pharmacodynamic mechanism by which HCTZ produced severe hyponatremia in this patient?

• A) HCTZ blocks NKCC2 in the TAL and abolishes the medullary concentration gradient, preventing ADH from concentrating the urine; the severe hyponatremia reflects pure volume depletion from excessive natriuresis that was not replaced by oral fluid intake; the high urine osmolality of 648 mOsm/kg reflects maximal ADH release in response to hypovolemia rather than any preserved concentrating ability
• B) HCTZ directly stimulates hypothalamic ADH synthesis through a pharmacological mechanism unrelated to osmolality or volume sensing; the resulting ADH excess produces a syndrome of inappropriate antidiuretic hormone secretion (SIADH) indistinguishable from other causes; the urine osmolality of 648 mOsm/kg reflects the ADH-driven collecting duct water reabsorption that HCTZ initiates
• C) HCTZ blocks NCC in the DCT — the cortical diluting segment — impairing the kidney's ability to generate dilute urine, while leaving the NKCC2-dependent medullary concentration gradient fully intact; nausea from the urinary tract infection provided a potent non-osmotic ADH stimulus, and ADH drove water reabsorption through AQP2 channels into the preserved hypertonic medullary interstitium, producing concentrated urine (urine osmolality 648 mOsm/kg) while the kidney was pharmacologically incapable of excreting free water as a dilute urine; elderly women represent the classic highest-risk demographic because of lower lean body mass, lower total body water, and high ADH responsiveness
• D) HCTZ caused hyponatremia by producing severe potassium depletion that shifted potassium out of cells in exchange for sodium, lowering plasma sodium; the hyponatremia is therefore a transcellular redistribution phenomenon rather than a water-handling problem; the elevated urine osmolality reflects aldosterone-driven sodium reabsorption in the collecting duct that is stimulated by the hypokalemia-induced secondary hyperaldosteronism
• E) HCTZ caused hyponatremia by blocking TRPV5-mediated calcium reabsorption in the DCT, raising urinary calcium and causing osmotic diuresis; the water lost with the calcium excretion was not replaced by oral intake; the high urine osmolality reflects calcium-driven urinary concentration as calcium crystallizes in the collecting duct and raises tubular fluid osmolality

2. [CASE 1 — QUESTION 2] Continuing with the same patient. The emergency physician confirms the diagnosis of severe thiazide-associated hyponatremia. The team discusses initial management. The sodium of 112 mEq/L with confusion represents symptomatic severe hyponatremia requiring careful correction. Which of the following correctly identifies the most important initial pharmacological action and explains why it is essential before other corrective measures can succeed?

• A) The most important initial pharmacological action is to discontinue HCTZ immediately; as long as NCC remains blocked in the DCT, the kidney cannot generate dilute urine regardless of how the ADH stimulus is addressed, the volume status is corrected, or fluid is restricted; removing the pharmacological block on the cortical diluting segment is the essential prerequisite that allows the kidney to begin excreting free water; failure to stop HCTZ means that all other interventions are working against an ongoing pharmacological barrier to free water excretion
• B) The most important initial pharmacological action is to administer demeclocycline, an ADH antagonist that blocks collecting duct AQP2 insertion; because the proximate cause of water retention is ADH acting on the collecting duct, pharmacological ADH antagonism is more targeted than stopping HCTZ, and demeclocycline will rapidly restore free water excretion independent of the NCC blockade
• C) The most important initial pharmacological action is to administer furosemide 40 mg IV to generate a natriuresis that dilutes the concentrated medullary interstitium; by disrupting the medullary gradient with furosemide, the ADH-driven collecting duct water retention mechanism is eliminated, raising serum sodium rapidly; HCTZ can be continued because the medullary gradient disruption by furosemide overrides the DCT dilution impairment
• D) The most important initial pharmacological action is to administer 3% saline at a rate of 1–2 mL/kg/hour without stopping HCTZ; the HCTZ does not need to be stopped because the hyponatremia is entirely caused by the ADH stimulus from nausea, which will resolve when the urinary tract infection is treated; once the ADH stimulus resolves, the kidney will restore free water excretion even with HCTZ continued
• E) The most important initial pharmacological action is to administer intravenous albumin to restore plasma oncotic pressure; HCTZ-induced hypoalbuminemia from urinary protein loss has lowered oncotic pressure, triggering ADH release through baroreceptor-mediated volume sensing; correcting oncotic pressure will suppress ADH and allow free water excretion to resume without stopping HCTZ

3. [CASE 1 — QUESTION 3] Continuing with the same patient. A medical student asks why this patient developed severe hyponatremia on HCTZ but would not have developed the same degree of hyponatremia had she been on furosemide instead. The attending asks the student to explain the mechanistic difference. Which of the following correctly explains why furosemide-treated patients are substantially less susceptible to this pattern of severe hyponatremia than thiazide-treated patients?

• A) Furosemide-treated patients are protected from severe hyponatremia because furosemide directly suppresses hypothalamic ADH release through a prostaglandin-mediated mechanism; without ADH, the collecting duct remains water-impermeable and free water cannot be retained regardless of any medullary gradient
• B) Furosemide-treated patients are protected because furosemide has a shorter half-life than HCTZ; the brief duration of NCC blockade from furosemide's metabolites means the diluting segment recovers function rapidly between doses, limiting the cumulative duration of impaired free water excretion
• C) Furosemide-treated patients are protected because furosemide blocks NKCC2 in the TAL and simultaneously increases aldosterone secretion, which upregulates ROMK channels in the collecting duct; the resulting potassium secretion generates a lumen-negative potential that opposes AQP2-mediated water entry, counteracting the ADH-driven water retention
• D) Furosemide-treated patients are protected because furosemide inhibits NCC in the DCT as a secondary pharmacological effect at therapeutic doses; the shared NCC blockade means both agents impair dilution equally, but furosemide's simultaneous NKCC2 blockade creates a compensatory free water diuresis that prevents serum sodium from falling as severely as with HCTZ alone
• E) Furosemide blocks NKCC2 in the TAL and disrupts the medullary concentration gradient that is essential for ADH-driven collecting duct water reabsorption; with the medullary gradient abolished, ADH cannot concentrate the urine effectively and produces only a near-isotonic urine regardless of ADH levels; this means that even with maximum non-osmotic ADH stimulation from nausea or other stimuli, the kidney cannot generate the highly concentrated urine that drives the disproportionate free water retention responsible for severe thiazide hyponatremia; loop diuretics impair both dilution and concentration, while thiazides impair only dilution — and it is the preservation of concentrating ability combined with impaired dilution that creates the dangerous thiazide hyponatremia substrate

4. [CASE 1 — QUESTION 4] Continuing with the same patient. Over the following 48 hours, sodium is corrected cautiously to 126 mEq/L, the urinary tract infection is treated, the patient's confusion resolves, and she is clinically stable. The medical team must now decide on long-term antihypertensive management. Her blood pressure before the acute illness was well-controlled on HCTZ. The attending asks the team what antihypertensive strategy is most appropriate going forward, given the severe hyponatremia event. Which of the following best identifies the correct approach and pharmacological rationale?

• A) HCTZ can be safely restarted at a lower dose of 12.5 mg daily; the hyponatremia was caused by the concurrent nausea providing an ADH stimulus, not by the HCTZ itself; at a lower dose, the NCC blockade will be incomplete and the diluting segment will retain partial function, preventing a recurrence of severe hyponatremia even if another ADH stimulus occurs
• B) Switching to a non-thiazide antihypertensive agent — such as an ACE inhibitor, angiotensin receptor blocker, or calcium channel blocker — is the appropriate strategy; all thiazide and thiazide-like diuretics (including chlorthalidone, indapamide, and metolazone) share the NCC-blockade-mediated dilution impairment mechanism that created the substrate for severe hyponatremia in this patient; restarting any NCC-blocking agent in a patient who has demonstrated severe thiazide hyponatremia carries a high recurrence risk, particularly given her age, sex, and demonstrated susceptibility; an agent that does not impair the cortical diluting segment avoids this substrate
• C) Chlorthalidone 12.5 mg daily is the appropriate substitute because unlike HCTZ it has a longer half-life and more gradual onset of NCC blockade; the slower NCC inhibition gives the kidney time to upregulate compensatory transport pathways in the DCT that prevent complete dilution impairment; chlorthalidone is therefore safe for this patient despite the HCTZ-induced hyponatremia
• D) Furosemide 40 mg daily is the appropriate antihypertensive substitute because it disrupts the medullary gradient rather than impairing dilution; even if non-osmotic ADH is released again, furosemide-treated patients cannot retain free water in a concentrated form, protecting against recurrent hyponatremia; furosemide simultaneously provides superior blood pressure control compared with thiazide-class agents based on ALLHAT trial data
• E) Spironolactone 25 mg daily is the appropriate antihypertensive substitute because mineralocorticoid receptor antagonism does not impair the cortical diluting segment and does not block NCC; spironolactone acts in the collecting duct on ENaC and is therefore safe from the dilution-impairment standpoint; its potassium-sparing effect also provides additional protection against the hypokalemia that contributed to the severe hyponatremia in this patient

5. [CASE 2 — QUESTION 1] A 67-year-old man with heart failure with reduced ejection fraction (HFrEF, ejection fraction 30%) and stage 4 CKD (GFR 26 mL/min/1.73 m²) is admitted with refractory volume overload. He is started on IV furosemide 80 mg twice daily. After 24 hours, net urine output is only 350 mL above intake, creatinine is stable at 3.2 mg/dL (baseline), and there are no concurrent nephrotoxins. Potassium is 3.9 mEq/L and magnesium is 1.9 mg/dL. A colleague suggests immediately adding metolazone for sequential nephron blockade. The attending disagrees and explains that furosemide dose escalation must come first. Which of the following best explains the pharmacokinetic and pharmacodynamic rationale for escalating the furosemide dose before adding metolazone?

• A) Furosemide dose escalation is not required before adding metolazone because the ceiling effect of loop diuretics is identical in CKD and in normal renal function; adding metolazone will block distal compensatory sodium reabsorption that is limiting the furosemide response, regardless of whether the upstream furosemide dose has reached NKCC2 threshold
• B) Metolazone should be added first because it blocks NCC in the DCT and increases sodium delivery to the TAL, raising the luminal sodium concentration at the NKCC2 binding site and sensitizing the transporter to furosemide at doses below the usual CKD threshold
• C) Furosemide dose escalation at a GFR of 26 mL/min is futile because NKCC2 expression is downregulated proportionally to GFR loss; at this GFR, fewer than 30% of TAL transporters are functional, and the remaining NKCC2 is already maximally occupied by 80 mg IV twice daily; adding metolazone is the only viable pharmacological strategy
• D) In stage 4 CKD, accumulated uremic organic anions compete with furosemide for OAT1 and OAT3 binding sites in the proximal tubule, reducing tubular drug secretion and lowering the achievable luminal NKCC2 concentration; furosemide 80 mg IV twice daily may be below the elevated threshold concentration required for meaningful NKCC2 blockade in this patient; escalating the dose saturates OAT competition and attempts to restore adequate luminal drug concentration; adding metolazone before the loop diuretic threshold is confirmed exposes the patient to the combined electrolyte risks of sequential blockade without first establishing that furosemide is producing any upstream natriuresis to intercept
• E) The attending is wrong and the colleague is correct; metolazone should be added immediately because the 350 mL net urine output proves that furosemide has completely failed to reach NKCC2 threshold, making further furosemide dose escalation pointless; the only rational next step is to bypass the failed loop diuretic with metolazone, which reaches NCC by passive diffusion and avoids OAT competition entirely

6. [CASE 2 — QUESTION 2] Continuing with the same patient. The team escalates furosemide to 200 mg IV twice daily. Over the next 24 hours net urine output improves to 700 mL above intake — confirming that the NKCC2 threshold has been reached — but this remains insufficient to achieve the target fluid removal of 1,500–2,000 mL per day. Creatinine and electrolytes remain stable. The attending asks what the next pharmacodynamically rational step is before adding metolazone. Which of the following best identifies the next step and explains the mechanism it targets?

• A) The next step is to immediately add metolazone 5 mg daily; the 700 mL net output at 200 mg twice daily confirms the NKCC2 ceiling has been reached and no further dose escalation can improve natriuresis; sequential nephron blockade is the only remaining pharmacological option before mechanical ultrafiltration
• B) The next step is to increase the furosemide dosing frequency from twice daily to three times daily before adding metolazone; when luminal furosemide concentration falls below the NKCC2 threshold between doses, the DCT and collecting duct activate compensatory sodium reabsorption — post-diuretic sodium avidity — during the pharmacodynamic dead zone; increasing frequency from twice to three times daily shortens each avidity window, reducing the sodium recovered between peaks and improving 24-hour net natriuresis without adding the electrolyte risks of sequential blockade
• C) The next step is to switch from furosemide to bumetanide 5 mg IV twice daily; bumetanide has approximately 40 times the potency of furosemide and a superior pharmacokinetic profile in CKD because it does not rely on OAT-mediated secretion; the switch will produce substantially greater NKCC2 blockade at an equivalent systemic dose and overcome the ceiling that furosemide has reached
• D) The next step is to add low-dose dopamine infusion at 2–3 mcg/kg/min to increase renal blood flow and GFR, enhancing furosemide delivery to NKCC2; the DOSE trial established that combining furosemide with dopamine produced superior natriuresis compared with dose escalation alone in stage 4 CKD
• E) The next step is to switch to continuous IV furosemide infusion at 20 mg/hour instead of twice-daily bolus dosing; the DOSE trial established that continuous infusion produces superior natriuresis compared with bolus dosing because it maintains luminal drug concentration above the NKCC2 threshold continuously rather than creating peaks and troughs; this avoids the post-diuretic avidity problem without requiring sequential blockade

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Three-times-daily furosemide improves but does not fully achieve target fluid removal. The team adds metolazone 5 mg before each furosemide dose. Over the following 24 hours the patient produces 2,800 mL net urine output and loses 2.1 kg. The next morning's labs show: serum potassium 2.4 mEq/L, serum magnesium 1.1 mg/dL, and serum creatinine 2.9 mg/dL (up from baseline 3.2 mg/dL — noting this represents a worsening from 3.2 to 2.9 is actually an improvement; correcting: creatinine is now 4.1 mg/dL, up from 3.2 baseline). Which of the following best explains the mechanism responsible for each of the three laboratory abnormalities?

• A) The hypokalemia (2.4 mEq/L) reflects the dramatically increased sodium delivery to the collecting duct from combined NKCC2 and NCC blockade driving intense ENaC-mediated sodium reabsorption, which generates a strongly lumen-negative potential that forces ROMK-mediated potassium secretion; the hypomagnesemia (1.1 mg/dL) reflects the amplified tubular flow and washout from sequential blockade further impairing the paracellular magnesium reabsorption in the TAL that depends on the lumen-positive potential abolished by furosemide; the creatinine rise (4.1 mg/dL) reflects rapid intravascular volume depletion from the 2,800 mL net diuresis reducing renal perfusion pressure and GFR faster than transcapillary refill could compensate
• B) All three laboratory abnormalities reflect a single mechanism: metolazone-induced secondary hyperaldosteronism from volume contraction; aldosterone upregulates ENaC (causing potassium secretion and hypokalemia), activates TRPM6 downregulation (causing hypomagnesemia), and constricts the afferent arteriole (causing the creatinine rise); all three will resolve when aldosterone levels normalize after metolazone is discontinued
• C) The hypokalemia reflects metolazone directly blocking ROMK channels in the collecting duct rather than NCC in the DCT; direct ROMK blockade forces potassium to accumulate in the tubular lumen and be reabsorbed passively; the resulting intracellular potassium excess drives a transcellular shift that paradoxically lowers serum potassium; hypomagnesemia reflects metolazone upregulating TRPM6 in the DCT, causing excessive active magnesium entry into DCT cells and paradoxical magnesium depletion from intracellular sequestration; the creatinine rise reflects afferent arteriolar constriction from metolazone blocking prostaglandin synthesis
• D) The hypokalemia reflects the combination of furosemide and metolazone both directly blocking Na/K-ATPase on the basolateral membrane of collecting duct principal cells, preventing potassium entry into the cell and forcing extracellular potassium to fall; hypomagnesemia reflects direct TRPM6 inhibition by both drugs; the creatinine rise reflects competitive inhibition of creatinine secretion by metolazone at OAT sites in the proximal tubule, raising measured serum creatinine without reflecting a true GFR reduction
• E) The hypokalemia, hypomagnesemia, and creatinine rise all reflect additive OAT competition from three organic anions (furosemide, metolazone, and uremic anions) simultaneously occupying proximal tubular secretory sites; the competition impairs tubular function at the PCT level, reducing potassium and magnesium secretion into the lumen and causing creatinine accumulation from impaired tubular creatinine secretion; these are pharmacokinetic rather than pharmacodynamic effects

8. [CASE 2 — QUESTION 4] Continuing with the same patient. The team administers potassium chloride 80 mEq IV over 8 hours. Repeat potassium the following morning is 2.6 mEq/L — an inadequate response to aggressive repletion. Magnesium remains at 1.1 mg/dL. A nephrology consultant explains that potassium replacement will fail until a specific electrolyte is corrected first. Which of the following best explains the cellular mechanism by which hypomagnesemia renders hypokalemia refractory to potassium replacement, and identifies the correct repletion sequence?

• A) Hypomagnesemia renders potassium replacement ineffective by reducing the activity of basolateral Na/K-ATPase in collecting duct principal cells; without adequate intracellular magnesium to stabilize the Na/K-ATPase alpha-subunit, the pump cannot transport potassium into the cell from the administered infusion; magnesium must be repleted first to restore Na/K-ATPase function before potassium supplementation can raise intracellular potassium stores
• B) Hypomagnesemia causes refractory hypokalemia by reducing aldosterone receptor affinity in collecting duct principal cells; without normal intracellular magnesium, the mineralocorticoid receptor cannot bind aldosterone effectively; paradoxically, this causes ligand-independent receptor activation that constitutively upregulates ENaC and ROMK, driving potassium secretion that cannot be suppressed by any amount of systemic potassium; magnesium repletion restores aldosterone receptor affinity and suppresses ENaC-ROMK constitutive activity
• C) Hypomagnesemia causes refractory hypokalemia by impairing NKCC2 activity in the TAL; without intracellular magnesium to stabilize NKCC2, the cotransporter functions at reduced capacity and allows more sodium to escape to the collecting duct; the increased distal sodium delivery drives ROMK-mediated potassium secretion that cannot be overcome by systemic supplementation; magnesium repletion restores NKCC2 function and reduces distal sodium delivery
• D) Hypomagnesemia causes refractory hypokalemia by activating a magnesium-sensing receptor on the basolateral membrane of the collecting duct that, when unoccupied, upregulates apical potassium channels through a cyclic AMP signaling cascade; magnesium repletion occupies the receptor, suppresses the cyclic AMP signal, and closes the apical potassium channels; potassium repletion can then proceed effectively once the cyclic AMP-driven potassium leak is pharmacologically reversed
• E) Intracellular magnesium normally acts as a voltage-dependent blocker of ROMK (Kir1.1) channels in the apical membrane of collecting duct principal cells, physically occluding the channel pore and limiting potassium secretion to physiologically appropriate rates; when furosemide-induced magnesiuresis depletes intracellular magnesium, ROMK channels lose this inhibitory block and remain constitutively open, producing obligatory potassium secretion into the tubular lumen that persists regardless of systemic potassium levels; potassium infused into the bloodstream simply exits through the persistently open ROMK channels faster than it can raise serum levels; magnesium must be repleted first to restore the intracellular ROMK block before potassium supplementation becomes effective

9. [CASE 3 — QUESTION 1] A 58-year-old man with bipolar I disorder has been stable on lithium carbonate for five years with consistent trough levels between 0.75 and 0.85 mEq/L. He also takes digoxin 0.125 mg daily for atrial fibrillation and heart failure with reduced ejection fraction (HFrEF). His primary care physician starts hydrochlorothiazide (HCTZ) 25 mg daily for ankle edema. Twelve days later he presents to the emergency department with confusion, coarse tremor, ataxia, and dysarthria. His serum lithium is 2.1 mEq/L, serum potassium is 2.8 mEq/L, serum magnesium is 1.3 mg/dL, and serum creatinine is 1.1 mg/dL (baseline). Serum digoxin level is 0.92 ng/mL (previously 0.78 ng/mL on the same dose). Which of the following best explains the mechanism by which HCTZ elevated lithium to toxic levels within twelve days?

• A) HCTZ elevated lithium by competing with lithium at NKCC2 in the TAL, blocking lithium reabsorption and paradoxically causing lithium to accumulate in the tubular lumen where it is passively reabsorbed in the collecting duct; this passive collecting duct reabsorption is not subject to dose-dependent modulation and therefore cannot be controlled by adjusting the lithium dose
• B) HCTZ elevated lithium by inducing hepatic CYP2D6, the isoenzyme responsible for lithium glucuronidation and renal elimination; impaired hepatic-renal elimination reduced lithium clearance by approximately 60% within the first week; the digoxin level also rose because both drugs share CYP2D6 as their primary metabolizing enzyme, and competitive inhibition at a shared metabolic site raised both drug levels simultaneously
• C) Lithium is freely filtered at the glomerulus (it is not protein-bound) and is reabsorbed in the proximal convoluted tubule (PCT) via NHE3 and other sodium-permeable transporters that cannot discriminate between sodium and lithium; HCTZ-induced NCC blockade in the DCT produces natriuresis and volume contraction that activates the renin-angiotensin system, upregulating NHE3-mediated sodium — and lithium — reabsorption in the PCT as a compensatory response; plasma lithium concentration rises as renal lithium clearance is reduced; thiazides carry the highest lithium toxicity risk of any diuretic class because the sustained natriuresis and volume contraction produce maximum compensatory PCT avidity
• D) HCTZ elevated lithium by blocking OAT-mediated lithium secretion into the proximal tubular lumen; lithium reaches the tubular lumen primarily by OAT secretion (analogous to furosemide), and HCTZ — being a more potent OAT competitor — displaced lithium from OAT binding sites and reduced its tubular secretion; the resulting lithium retention raised plasma levels within days
• E) HCTZ elevated lithium by reducing GFR through afferent arteriolar vasoconstriction mediated by COX-independent prostaglandin-thromboxane imbalance; the reduced GFR decreased filtered lithium load below the tubular maximum for reabsorption, paradoxically increasing the fraction of filtered lithium that was reabsorbed; the creatinine did not rise because thromboxane-mediated vasoconstriction preferentially affects lithium handling without reducing inulin clearance

10. [CASE 3 — QUESTION 2] Continuing with the same patient. HCTZ is immediately discontinued, lithium is held, and supportive care is initiated. The patient recovers over 72 hours. His psychiatrist confirms that lithium must be continued long-term and that the ankle edema also requires ongoing pharmacological management. A pharmacology consultant is asked which diuretic agent can most safely be used in this patient going forward and why. Which of the following best identifies the preferred diuretic and explains the mechanistic basis for its relative safety in a lithium-treated patient?

• A) Furosemide is the preferred diuretic because, unlike HCTZ, it does not block NCC; loop diuretics act in the TAL on NKCC2 and produce acute high-volume diuresis that, through a volume-sensing mechanism, activates compensatory NKCC2 upregulation rather than PCT NHE3 upregulation; the NKCC2-driven compensation reabsorbs sodium without lithium because NKCC2 specifically excludes lithium from its cotransport mechanism
• B) Spironolactone is the preferred diuretic because mineralocorticoid receptor antagonism reduces aldosterone-driven sodium reabsorption in the collecting duct without generating any volume contraction or PCT sodium avidity; by reducing aldosterone rather than blocking a sodium transporter, spironolactone avoids the PCT NHE3 upregulation that reabsorbs lithium; it is also potassium-sparing, which addresses the hypokalemia that contributes to the digoxin toxicity risk in this patient
• C) Chlorthalidone is the preferred thiazide substitute because its longer half-life of 40–60 hours produces slower, more gradual volume contraction than HCTZ; the gradual onset of PCT NHE3 upregulation allows time for lithium dose adjustment before toxic levels accumulate; daily lithium monitoring for the first two weeks of chlorthalidone initiation is sufficient to safely manage the interaction
• D) Amiloride is the preferred diuretic because it blocks ENaC in the collecting duct, producing modest sodium loss without generating the degree of PCT sodium avidity that drives lithium reabsorption; amiloride acts at the final nephron segment and does not trigger the renin-angiotensin system-mediated NHE3 upregulation in the PCT that reabsorbs lithium alongside sodium; amiloride does not significantly increase lithium plasma concentrations and is the established safe alternative when diuresis is required in a lithium-treated patient
• E) Torsemide is the preferred diuretic because its predominantly hepatic metabolism makes it pharmacokinetically independent of the renal handling pathways that govern lithium clearance; because torsemide does not reach the tubular lumen via OAT secretion in a way that competes with lithium, it has no effect on lithium renal handling and is safe to use with lithium at any dose without monitoring

11. [CASE 3 — QUESTION 3] Continuing with the same patient. The team notes that the digoxin level rose from 0.78 ng/mL (pre-HCTZ) to 0.92 ng/mL despite no change in the digoxin dose, and that the potassium is 2.8 mEq/L and magnesium 1.3 mg/dL. Although the digoxin level remains below 1.0 ng/mL, the cardiology fellow is concerned that the patient may be at risk for digoxin toxicity given the electrolyte derangements. Which of the following best explains why the combination of hypokalemia and hypomagnesemia increases digoxin toxicity risk even when the plasma digoxin level remains within the conventional therapeutic range?

• A) Hypokalemia and hypomagnesemia increase digoxin toxicity by activating phosphodiesterase in cardiomyocytes, increasing intracellular cyclic AMP and driving excessive calcium influx through L-type channels; this calcium overload amplifies digoxin's positive inotropic effect to the point of triggered automaticity, and the digoxin level does not capture this calcium-mediated toxicity
• B) Potassium and magnesium are physiological competitors of digoxin at the extracellular face of the Na/K-ATPase alpha-subunit; when potassium is depleted to 2.8 mEq/L, the competitive antagonism that normally limits digoxin's pump occupancy at any given plasma concentration is reduced, and digoxin binds the Na/K-ATPase with greater affinity and occupies a greater fraction of cardiac pump molecules; concurrently, hypomagnesemia depletes intracellular magnesium, disinhibiting ROMK channels in the collecting duct and producing obligatory potassium secretion that perpetuates and deepens the hypokalemia; the two mechanisms are self-reinforcing — hypomagnesemia sustains the hypokalemia that amplifies digoxin binding — and the conventional therapeutic range was defined at normal electrolyte concentrations, making it an unreliable safety threshold when both cations are depleted
• C) Hypokalemia increases digoxin toxicity by inducing hepatic CYP3A4 upregulation, which paradoxically inhibits digoxin metabolism by saturating the enzyme with potassium-depleted substrate; the resulting digoxin accumulation exceeds the plasma level because muscle potassium depletion competes with digoxin for intracellular binding sites, concentrating digoxin in the cardiac myocyte
• D) Hypomagnesemia increases digoxin toxicity by directly blocking the Na/K-ATPase at the same binding site as digoxin; when magnesium and digoxin occupy the same extracellular site simultaneously, a conformational change increases the duration of Na/K-ATPase inhibition per digoxin molecule; this pharmacodynamic synergy is not reflected in the plasma digoxin level, which measures total drug concentration without accounting for the magnesium-digoxin co-inhibitory state
• E) Hypokalemia increases digoxin toxicity by increasing the resting membrane potential of cardiomyocytes, bringing the cell closer to the threshold for spontaneous depolarization; digoxin's vagotonic effect on AV nodal conduction is amplified in hyperpolarized cells because the vagal cholinergic pathway is more efficient at suppressing automaticity in cells with a more negative resting potential, paradoxically increasing the risk of AV block at any given digoxin concentration

12. [CASE 3 — QUESTION 4] Continuing with the same patient. The team must now manage the electrolyte abnormalities (potassium 2.8 mEq/L, magnesium 1.3 mg/dL) while monitoring for digoxin toxicity and ensuring lithium levels fall safely. A pharmacology consultant is asked to specify the correct electrolyte repletion sequence and the rationale for prioritizing one electrolyte over the other. Which of the following correctly identifies the priority repletion sequence and the mechanistic justification for each step?

• A) Magnesium must be repleted first: depleted intracellular magnesium has disinhibited ROMK channels in the collecting duct, producing obligatory potassium secretion that renders potassium replacement ineffective until magnesium is corrected; once magnesium is repleted and ROMK channels are re-blocked, potassium supplementation can effectively raise serum potassium; restoring potassium then re-establishes competitive antagonism at the Na/K-ATPase alpha-subunit, reducing digoxin binding affinity and lowering digoxin toxicity risk; lithium levels should be rechecked after HCTZ is discontinued and PCT sodium avidity normalizes, and digoxin levels should be re-evaluated in the context of normalized electrolytes before any dose adjustment
• B) Potassium must be repleted first because hypokalemia is the more immediately dangerous abnormality for digoxin toxicity; once potassium is restored above 4.0 mEq/L, competitive antagonism at the Na/K-ATPase is restored and digoxin toxicity risk falls; magnesium should then be replaced as a secondary measure; lithium replacement should occur simultaneously with potassium to prevent prolonged lithium washout from the hyperosmolar diuresis that accompanies hypokalemia correction
• C) Magnesium and potassium should be repleted simultaneously in equal molar ratios through a combined magnesium-potassium phosphate infusion; the phosphate anion is required to stabilize both cations intracellularly and prevent transcellular redistribution; lithium should be administered as a single loading dose 24 hours after electrolyte correction to prevent lithium from competing with potassium for intracellular uptake during the repletion phase
• D) No specific electrolyte repletion order is required because magnesium and potassium are independent deficits that correct through separate tubular mechanisms; potassium corrects through dietary intake restored by improved appetite when lithium toxicity resolves, and magnesium corrects through TRPM6 reactivation as HCTZ-mediated TRPM6 downregulation resolves over days; the most urgent action is administering lithium-chelating agents to accelerate renal lithium excretion
• E) Potassium must be repleted first because hypokalemia — not hypomagnesemia — is the driver of ROMK channel opening; when serum potassium falls below 3.0 mEq/L, collecting duct principal cells activate a potassium-sensing receptor that opens ROMK constitutively; restoring serum potassium above 3.5 mEq/L closes the potassium-sensing receptor and allows ROMK to resume regulated secretion; magnesium can then be repleted as a secondary measure once ROMK is closed

13. [CASE 4 — QUESTION 1] A 62-year-old woman with known primary hyperparathyroidism (PTH 138 pg/mL, previously managed conservatively) presents with nausea, constipation, polyuria, and mild confusion. Serum calcium is 13.2 mg/dL (up from 11.1 mg/dL four months ago). Review of her medication history reveals that HCTZ 25 mg daily was started six weeks ago by her cardiologist for newly diagnosed stage 1 hypertension. Her creatinine is 1.0 mg/dL and GFR is 74 mL/min/1.73 m². The internist asks the team to explain how HCTZ contributed to the worsening hypercalcemia. Which of the following correctly identifies the tubular mechanism by which HCTZ reduced urinary calcium excretion and thereby compounded the hypercalcemia?

• A) HCTZ contributed to hypercalcemia by blocking NKCC2 in the TAL and abolishing the lumen-positive transepithelial potential that normally drives paracellular calcium secretion into the tubular lumen; with paracellular calcium secretion eliminated, urinary calcium fell and serum calcium rose; furosemide, which restores the lumen-positive potential, is the appropriate acute intervention
• B) HCTZ contributed to hypercalcemia by stimulating parathyroid hormone (PTH) secretion through a calcium-sensing receptor-independent volume contraction-mediated mechanism at the parathyroid gland; the elevated NCC blockade signal is transmitted humorally to the parathyroid via a renal tubular endocrine axis; the hypercalcemia reflects combined PTH excess from the primary disease and HCTZ-augmented PTH secretion
• C) HCTZ contributed to hypercalcemia by inducing nephrocalcinosis in the distal convoluted tubule; the blocked NCC transporter triggers intracellular calcium accumulation in DCT cells, leading to calcium phosphate precipitation and progressive calcium deposition in the tubular epithelium; the calcified DCT cells release calcium into the interstitium and then the systemic circulation, raising serum calcium
• D) HCTZ contributed to hypercalcemia by directly activating PTH receptors on DCT cells through a molecular mimicry mechanism; the sulfonamide group of HCTZ shares structural homology with the PTH N-terminal fragment; the PTH receptor activation by HCTZ upregulates TRPV5 through a cyclic AMP pathway independent of actual PTH binding and reduces urinary calcium
• E) HCTZ contributed to hypercalcemia through its calcium-sparing mechanism: NCC blockade in the DCT reduces intracellular sodium in DCT cells, enhancing basolateral NCX1 activity and increasing apical TRPV5-mediated calcium entry from the tubular lumen, reducing urinary calcium excretion by 30–50%; in this patient with primary hyperparathyroidism, this pharmacological reduction in renal calcium excretion removed the kidney's compensatory capacity to dispose of PTH-driven calcium input from bone resorption and increased intestinal absorption, allowing serum calcium to rise from 11.1 to 13.2 mg/dL over six weeks

14. [CASE 4 — QUESTION 2] Continuing with the same patient. HCTZ is immediately discontinued. The team now plans acute management of the symptomatic hypercalcemia (calcium 13.2 mg/dL with confusion). An intern suggests starting furosemide immediately to promote calciuresis. The attending stops the intern and corrects the management plan. Which of the following best explains why furosemide must not be given as the first intervention, and identifies the correct management sequence?

• A) Furosemide must not be given first because it will activate the lumen-positive potential in the TAL and drive paracellular calcium reabsorption, paradoxically worsening the hypercalcemia; the correct first intervention is spironolactone, which blocks aldosterone-driven calcium reabsorption in the collecting duct and allows urinary calcium to rise passively before furosemide is added
• B) Furosemide must not be given first because it blocks NKCC2 and thereby increases TRPV5-mediated calcium reabsorption in the DCT, the same mechanism as HCTZ; furosemide at standard doses actually has a calcium-retaining effect in volume-depleted patients; the correct first intervention is amiloride, which blocks ENaC without affecting NKCC2 or DCT calcium handling
• C) Furosemide must not be given first because hypercalcemia causes nephrogenic diabetes insipidus through AQP2 suppression, producing polyuria and volume depletion; administering furosemide to a volume-depleted patient causes further volume contraction, reduces GFR, and reduces tubular calcium delivery to NKCC2, paradoxically worsening hypercalcemia by concentrating calcium in a smaller extracellular fluid volume and reducing the calciuresis that furosemide would otherwise produce; the correct sequence is to administer aggressive IV normal saline first to restore intravascular volume and GFR, promoting passive calciuresis through increased tubular flow, and then to add furosemide once volume is repleted to sustain urinary calcium excretion through its calciuric mechanism — abolishing the TAL lumen-positive potential that drives paracellular calcium reabsorption
• D) Furosemide must not be given first because it will cause severe metabolic alkalosis in this patient whose primary hyperparathyroidism has already compromised her bicarbonate buffering capacity; the alkalosis will shift ionized calcium to the protein-bound fraction, falsely lowering the measured total calcium and masking the severity of hypercalcemia; the correct first intervention is to correct the alkalosis with ammonium chloride before any diuretic is given
• E) Furosemide must not be given first because it will raise serum PTH levels by reducing plasma calcium transiently; the acute calcium-sensing receptor response to furosemide-induced calciuresis stimulates PTH secretion that immediately restores calcium to pre-treatment levels; the correct first intervention is cinacalcet to suppress PTH before any calciuretic agent is given

15. [CASE 4 — QUESTION 3] Continuing with the same patient. After 36 hours of aggressive IV saline followed by furosemide, her serum calcium has corrected to 10.6 mg/dL and her symptoms have resolved. She requires ongoing antihypertensive therapy for her stage 1 hypertension. The endocrinology team is evaluating her for parathyroidectomy, which will take several months to arrange. In the interim, the team must select a long-term antihypertensive agent. Which of the following correctly identifies the most appropriate antihypertensive choice for this patient and explains the pharmacological rationale?

• A) Chlorthalidone is the appropriate long-term antihypertensive because unlike HCTZ it has a half-life of 40–60 hours that provides more gradual and sustained NCC blockade; this slower onset of calcium-sparing effect allows the parathyroid gland time to adjust PTH secretion downward through negative feedback, preventing the acute calcium surge seen with HCTZ; at maintenance doses, chlorthalidone's calcium-sparing effect is too small to produce clinically significant hypercalcemia in a patient with well-controlled primary hyperparathyroidism
• B) Furosemide 40 mg daily is the appropriate long-term antihypertensive because it has a calciuric rather than calcium-sparing effect; daily furosemide will promote ongoing urinary calcium excretion and reduce serum calcium, simultaneously managing both the hypertension and the hypercalcemia of primary hyperparathyroidism; furosemide's ALLHAT-supported outcome data establish it as a first-line agent in high-risk hypertensive patients
• C) Spironolactone 25 mg daily is the appropriate long-term antihypertensive because mineralocorticoid receptor antagonism does not affect DCT calcium handling, avoids NCC blockade, and provides blood pressure reduction through aldosterone-independent sodium retention pathways; in primary hyperparathyroidism, elevated PTH causes secondary hyperaldosteronism that spironolactone can specifically target
• D) An ACE inhibitor, angiotensin receptor blocker (ARB), or calcium channel blocker (CCB) is the appropriate long-term antihypertensive choice; all thiazide and thiazide-like diuretics — including chlorthalidone and indapamide — share the NCC-blockade-mediated calcium-sparing mechanism that compounded the hypercalcemia and are therefore contraindicated in this patient until parathyroidectomy corrects the underlying calcium excess; furosemide is not guideline-supported as first-line antihypertensive monotherapy; agents that do not affect tubular calcium handling are the safest and most appropriate choice
• E) Indapamide is the appropriate long-term antihypertensive because its primary blood pressure-lowering effect at low doses is mediated by vascular smooth muscle calcium channel antagonism rather than NCC blockade; at antihypertensive doses, indapamide's NCC inhibition is clinically negligible, and its calcium channel antagonism in vascular smooth muscle does not affect tubular calcium reabsorption, making it safe for use in primary hyperparathyroidism

16. [CASE 4 — QUESTION 4] Continuing with the same patient. She undergoes successful parathyroidectomy three months later. PTH normalizes to 42 pg/mL and serum calcium is 9.2 mg/dL. She is now evaluated for long-term antihypertensive management. At her post-operative visit, she also reports a new episode of right flank pain; urinalysis shows calcium oxalate crystals and 24-hour urinary calcium excretion is 310 mg/day (elevated). Her physician identifies an opportunity to select a single antihypertensive agent that optimally addresses both her hypertension and her hypercalciuria-driven nephrolithiasis risk. Which of the following best identifies the appropriate agent and integrates the pharmacological rationale for both indications now that her hyperparathyroidism has been cured?

• A) Furosemide is the optimal agent because its calciuric effect directly reduces urinary calcium supersaturation and prevents calcium oxalate stone nucleation; the DOSE trial demonstrates furosemide's superiority in managing volume-related conditions, and this evidence base extends to nephrolithiasis prevention through sustained calciuresis; ALLHAT outcome data further support furosemide as first-line for hypertension in high-risk patients
• B) Chlorthalidone is the optimal agent: its half-life of 40–60 hours provides more consistent 24-hour blood pressure control than HCTZ (guideline-preferred by ALLHAT outcome data); simultaneously, its NCC-blockade-mediated calcium-sparing effect reduces urinary calcium by 30–50% through the NCX1-TRPV5 transcellular pathway in the DCT, directly lowering calcium oxalate supersaturation and providing first-line pharmacological stone prophylaxis; with primary hyperparathyroidism cured and calcium normalized, a thiazide-class agent no longer carries the risk of compounding hypercalcemia and is safe to use; chlorthalidone therefore achieves guideline-preferred antihypertensive efficacy and stone prevention with a single agent
• C) Spironolactone is the optimal agent because it addresses both indications simultaneously: mineralocorticoid receptor antagonism lowers blood pressure and reduces aldosterone-driven urinary calcium excretion through upregulation of TRPV5 in the DCT; spironolactone's stone-prevention evidence base is supported by the PATHWAY-2 trial, which demonstrated superior blood pressure reduction and reduced stone events compared with both bisoprolol and doxazosin in resistant hypertension
• D) Hydrochlorothiazide is the preferred agent because it is available in fixed-dose combinations that include calcium supplements, making it uniquely suited for a patient with a history of calcium stone disease requiring calcium replenishment; the fixed-dose HCTZ-calcium combination prevents stones by saturating intestinal calcium absorption and reducing urinary calcium through NCC blockade simultaneously
• E) Amiloride is the optimal dual-purpose agent because it blocks ENaC in the collecting duct, reducing sodium reabsorption and lowering blood pressure, while simultaneously blocking a calcium channel in the collecting duct through a shared ion channel mechanism; its potassium-sparing effect prevents the hypokalemia that promotes uric acid crystallization in thiazide-treated patients with stone disease

17. [CASE 5 — QUESTION 1] A 70-year-old man with HFrEF (ejection fraction 28%) and nephrotic syndrome (24-hour urine protein 10.8 g, serum albumin 1.7 g/dL, GFR 38 mL/min/1.73 m²) presents with progressive anasarca. Oral furosemide has been escalated to 200 mg twice daily over two weeks with minimal natriuretic response. He has no concurrent NSAID use and creatinine is stable. A nephrology fellow presents this case to the attending as an example of compounded pharmacokinetic resistance and asks the team to identify both barriers. Which of the following correctly identifies the two pharmacokinetic barriers operating simultaneously in this patient and explains why each is distinct?

• A) The first barrier is OAT competition: at a GFR of 38 mL/min/1.73 m², accumulated uremic organic anions compete with furosemide for OAT1 and OAT3 binding sites on the basolateral membrane of the PCT, reducing the rate of furosemide secretion into the tubular lumen and lowering luminal drug concentration below the NKCC2 threshold; the second barrier is intraluminal albumin binding: nephrotic syndrome delivers large quantities of albumin through the leaky glomerular barrier into the tubular filtrate, where this intraluminal albumin re-binds furosemide (which is approximately 98% protein-bound in plasma) and sequesters it from the NKCC2 luminal binding site; these two barriers attack furosemide delivery at sequential steps — basolateral secretion and luminal drug availability — in a way that neither CKD nor nephrotic syndrome alone produces
• B) The first barrier is reduced GFR causing decreased glomerular filtration of furosemide; because furosemide reaches NKCC2 primarily by filtration, the GFR of 38 mL/min reduces filtered drug delivery below the threshold; the second barrier is hypoalbuminemia increasing the volume of distribution of furosemide, distributing drug into peripheral tissues rather than the kidney; IV administration corrects both barriers simultaneously by delivering drug directly to the renal artery
• C) The first barrier is hepatic first-pass metabolism increased by the hypoalbuminemia of nephrotic syndrome; lower plasma protein binding accelerates hepatic extraction of furosemide, reducing systemic bioavailability below the level needed for OAT secretion; the second barrier is aldosterone-mediated NCC upregulation in the DCT from secondary hyperaldosteronism driven by volume depletion; adding spironolactone to block aldosterone will correct the second barrier
• D) The first barrier is furosemide inactivation by albumin in the systemic circulation before it reaches OAT; urinary proteins that back-leak into the plasma bind and inactivate furosemide during transit from gut to kidney; the second barrier is upregulated MRP2 efflux transporters in the PCT luminal membrane from nephrotic syndrome-associated uremia, actively pumping furosemide back into tubular cells before it can reach NKCC2; switching to torsemide corrects both barriers because torsemide is not an MRP2 substrate
• E) Both barriers reflect a single mechanism: nephrotic syndrome reduces OAT expression through an albumin-mediated transcriptional downregulation in PCT cells, and CKD reduces OAT activity through uremic anion competition; both conditions attack OAT at different levels of the same secretory pathway, producing compounded reductions in furosemide secretion; the barriers are not truly distinct — they share the same OAT secretory bottleneck

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The team switches to IV furosemide at high doses. A student asks whether switching from oral to IV administration fully resolves both pharmacokinetic barriers or only one. The attending asks the team to analyze which barrier IV administration addresses and which one persists. Which of the following correctly identifies which barrier IV administration corrects and which one requires a different strategy to overcome?

• A) IV administration corrects both barriers simultaneously: the IV route bypasses gastrointestinal absorption variability and eliminates the need for OAT-mediated secretion entirely, as IV furosemide is delivered directly to the renal artery and passively diffuses from peritubular capillaries into tubular cells by lipid diffusion; with no OAT step required, uremic anion competition is bypassed, and the intraluminal albumin barrier is simultaneously corrected because IV furosemide carries a different protein-binding profile that prevents re-binding to intraluminal albumin
• B) IV administration corrects the intraluminal albumin barrier only: IV furosemide bypasses the tubular lumen entirely by crossing the peritubular capillary wall and diffusing directly to the NKCC2 basolateral face, which does not face intraluminal albumin; the OAT competition barrier persists because IV furosemide still must be secreted by OAT into the lumen to reach NKCC2's luminal binding site; the intraluminal albumin is never encountered in IV-administered drug
• C) IV administration corrects neither barrier: both the OAT competition barrier and the intraluminal albumin barrier are independent of the route of administration; IV furosemide must still be secreted by OAT into the tubular lumen (so OAT competition persists), and once in the lumen it binds to intraluminal albumin with the same affinity as orally administered furosemide (so the luminal albumin barrier persists); the only strategies that can overcome both barriers are high-dose IV furosemide (flooding the lumen with enough drug that even after albumin binding, free drug exceeds NKCC2 threshold) and coinfusion with albumin, though evidence for albumin coinfusion remains limited
• D) IV administration corrects the OAT competition barrier only: IV furosemide achieves higher peak plasma concentrations that saturate OAT binding sites in excess of uremic anion competition, restoring adequate luminal delivery; the intraluminal albumin barrier persists because it is downstream of OAT secretion and reflects the protein content of the tubular filtrate, which is determined by glomerular permeability rather than the route of drug administration
• E) IV administration corrects only the oral absorption barrier — not either of the two pharmacokinetic barriers relevant to this patient; oral furosemide in this patient additionally suffers from bowel wall edema-impaired intestinal absorption in the setting of severe hypoalbuminemia and volume overload; switching to IV ensures that the systemic furosemide level reliably reflects the intended dose; however, the OAT competition barrier from uremic anions and the intraluminal albumin barrier from nephrotic proteinuria both persist with IV administration, because IV furosemide still requires OAT-mediated basolateral secretion to reach the tubular lumen and encounters the same intraluminal albumin once it arrives; the strategy to overcome the remaining barriers is to administer sufficiently high IV doses to saturate OAT competition and ensure that enough free luminal drug remains after intraluminal albumin binding to achieve NKCC2 threshold concentrations

19. [CASE 5 — QUESTION 3] Continuing with the same patient. With high-dose IV furosemide (320 mg twice daily) the patient achieves partial but insufficient natriuresis — approximately 900 mL net output per day. The team adds metolazone 5 mg before each furosemide dose and achieves 2,200 mL net output per day. A student asks how metolazone can improve natriuresis when furosemide pharmacokinetics are so severely impaired in this patient. Which of the following best explains why sequential nephron blockade with metolazone remains pharmacodynamically effective even in the setting of combined CKD and nephrotic syndrome pharmacokinetic impairment of furosemide?

• A) Metolazone is not affected by either pharmacokinetic barrier because it bypasses OAT-mediated secretion entirely through passive lipid diffusion and is not protein-bound, so intraluminal albumin cannot inactivate it; metolazone therefore reaches NCC at full concentration regardless of CKD or nephrotic syndrome, explaining why it succeeds where furosemide fails and why the combination is always superior to furosemide monotherapy regardless of the degree of furosemide pharmacokinetic impairment
• B) Metolazone works in this setting because it directly inhibits NKCC2 at a different binding site from furosemide, providing additive NKCC2 blockade that compensates for the reduced furosemide occupancy from pharmacokinetic impairment; the combination therefore achieves maximal NKCC2 blockade by having two drugs work at the same transporter simultaneously
• C) The 900 mL net output on furosemide monotherapy confirms that some NKCC2 blockade is occurring — a meaningful quantity of sodium is escaping the TAL despite the pharmacokinetic barriers; chronic elevated sodium delivery to the DCT has caused structural DCT hypertrophy and NCC upregulation as a compensatory adaptation, allowing the DCT to reclaim a large fraction of this upstream natriuresis before it reaches the urine; metolazone blocks these structurally upregulated NCC transporters in the hypertrophied DCT, preventing distal sodium recovery and allowing a much greater fraction of the furosemide-generated upstream natriuresis to reach the collecting duct and ultimately the urine
• D) Metolazone works because it is a prodrug activated by intestinal esterases to a metabolite that is not protein-bound; the activated metabolite circulates freely and is filtered at the glomerulus in proportion to the free drug fraction; unlike furosemide, the metolazone metabolite does not rely on OAT secretion and is not subject to intraluminal albumin binding, explaining its full efficacy despite furosemide's pharmacokinetic impairment in this patient
• E) Metolazone corrects the furosemide pharmacokinetic barriers by chelating uremic organic anions in the plasma, freeing OAT binding sites for furosemide secretion; simultaneously, metolazone's high albumin binding displaces furosemide from intraluminal albumin, releasing free furosemide to reach NKCC2; metolazone therefore does not produce its own natriuresis but rather acts as a pharmacokinetic rescue agent that restores furosemide's activity

20. [CASE 5 — QUESTION 4] Continuing with the same patient. The patient develops a gram-negative bacteremia during his hospitalization and is started on gentamicin for five days alongside his high-dose IV furosemide. Three days after completing gentamicin, he reports difficulty hearing high-pitched sounds bilaterally. Audiometry confirms sensorineural hearing loss predominantly in the 4,000–8,000 Hz range. The team recognizes this as drug-induced ototoxicity. Which of the following best explains why the combination of high-dose loop diuretics and aminoglycosides carries additive ototoxic risk, and identifies the distinct mechanisms by which each drug class damages the cochlea?

• A) Loop diuretics and aminoglycosides cause ototoxicity through an identical shared mechanism: both drugs bind to NKCC1 in the stria vascularis of the cochlea and competitively inhibit the same active site; when administered concurrently, the combined occupancy of NKCC1 exceeds what either drug achieves alone, producing additive endolymph ion transport failure; the synergistic risk is purely a function of NKCC1 occupancy from two competing ligands
• B) Loop diuretics cause ototoxicity by alkalinizing the endolymph through NKCC1 blockade, while aminoglycosides cause ototoxicity by acidifying the endolymph through inhibition of the H⁺-ATPase in the stria vascularis; the combination of alkaline and acid-phase endolymph destabilization produces greater osmotic hair cell injury than either agent alone; the pH changes are synergistic rather than additive
• C) Loop diuretics cause ototoxicity by blocking NKCC1 in the basolateral membrane of stria vascularis marginal cells, disrupting the active ion transport that generates and maintains the endocochlear potential; without the endocochlear potential, mechanotransduction in cochlear hair cells fails; aminoglycosides cause ototoxicity through a completely unrelated mechanism — inhibition of mitochondrial protein synthesis — that produces cochlear hair cell dropout through energy failure rather than endolymph ion disturbance; the combination is additive because both drugs independently impair hair cell function through entirely separate pathways
• D) Loop diuretics cause ototoxicity by inhibiting NKCC1 in the stria vascularis of the cochlea, disrupting the active sodium-potassium-chloride transport that generates the endocochlear potential; loss of the endocochlear potential impairs mechanotransduction in cochlear hair cells and produces sensorineural hearing loss preferentially in high-frequency ranges; aminoglycosides cause ototoxicity through a separate but anatomically convergent mechanism — generation of reactive oxygen species (ROS) in cochlear outer hair cells, with selective accumulation in the basal turn of the cochlea (responsible for high-frequency detection) causing oxidative hair cell death; the two mechanisms are distinct but both target cochlear hair cell viability through different pathways, producing additive damage that exceeds what either agent causes alone; concurrent administration at high doses and for extended duration amplifies this combined injury
• E) Aminoglycosides do not cause cochlear ototoxicity; their auditory toxicity is exclusively vestibulotoxic, affecting the cristae ampullares of the semicircular canals; loop diuretics cause cochlear ototoxicity through NKCC1 inhibition; the patient's sensorineural hearing loss reflects loop diuretic toxicity exclusively, and the concurrent gentamicin caused only vestibular dysfunction that was not tested on the audiogram

21. [CASE 6 — QUESTION 1] A 65-year-old man with HFrEF (ejection fraction 31%) and atrial fibrillation is managed on furosemide 80 mg daily and digoxin 0.125 mg daily. His cardiologist switches him to torsemide 20 mg daily six months ago because of erratic furosemide responses in the setting of stage 3b CKD (GFR 35 mL/min/1.73 m²). He has been stable on torsemide with consistent dry weight maintenance. He is now admitted with alcoholic hepatitis: bilirubin 8.4 mg/dL, INR 1.9, albumin 2.6 g/dL, and creatinine 1.8 mg/dL (baseline). His torsemide dose is continued unchanged. Over the next ten days his urine output increases dramatically, he loses 5.8 kg, and creatinine rises to 3.1 mg/dL. Serum potassium is 2.4 mEq/L and magnesium is 1.1 mg/dL. The admitting team asks why torsemide — previously well-tolerated — is now causing over-diuresis and AKI. Which of the following best explains the pharmacokinetic mechanism?

• A) Alcoholic hepatitis reduced hepatic albumin synthesis, increasing the free plasma fraction of torsemide; the higher free drug fraction dramatically accelerated renal OAT-mediated secretion, raising luminal torsemide concentration above the NKCC2 ceiling; the increase in luminal drug above the ceiling does not produce more NKCC2 blockade but does cause direct NKCC2 toxicity that permanently damages TAL cells, explaining why the natriuresis persists even after torsemide is held
• B) Torsemide is approximately 80% hepatically metabolized via CYP2C9; alcoholic hepatitis has impaired CYP2C9 activity — consistent with the prolonged INR reflecting reduced hepatic synthetic function — reducing torsemide clearance and extending its half-life beyond the usual 3–4 hours; with each successive daily dose administered before the prior dose is fully cleared, torsemide progressively accumulates in plasma; rising plasma concentrations increase OAT-mediated luminal drug delivery and produce supratherapeutic NKCC2 blockade, generating excessive natriuresis; the resulting volume depletion reduces renal perfusion and explains the creatinine rise; the electrolyte depletion reflects the amplified collecting duct sodium delivery driving ROMK-mediated kaliuresis
• C) Torsemide is causing over-diuresis because alcoholic hepatitis has stimulated hepatic conversion of torsemide to an active metabolite with 10-fold greater NKCC2 affinity than the parent compound; this metabolite accumulates in the tubular lumen because it is not a substrate for OAT-mediated back-secretion; the standard torsemide plasma level assay does not detect this metabolite, leading to underestimation of true pharmacological activity
• D) The over-diuresis reflects a drug interaction between torsemide and alcohol-derived acetaldehyde; acetaldehyde inhibits OAT1 and OAT3 in the proximal tubule, but paradoxically increases torsemide luminal concentration because acetaldehyde also blocks NKCC2-independent sodium reabsorption pathways, directing all tubular sodium through NKCC2 where torsemide then achieves higher percent blockade at the same luminal concentration
• E) Alcoholic hepatitis caused portal hypertension that diverted blood flow from the portal to the systemic circulation, increasing renal blood flow and GFR above baseline; the higher GFR delivered more torsemide to the kidney per unit time through increased OAT substrate presentation, raising luminal torsemide concentration above the threshold it was achieving at baseline GFR; the over-diuresis therefore reflects pharmacokinetically enhanced drug delivery from the hepatorenal hemodynamic shift

22. [CASE 6 — QUESTION 2] Continuing with the same patient. The team holds torsemide for 48 hours; urine output returns to baseline and creatinine improves to 2.2 mg/dL. They must now select a loop diuretic for ongoing management of his volume status during the hepatitis recovery phase. The attending asks the team to explain why furosemide is now pharmacokinetically preferable to torsemide in this patient, despite the stage 3b CKD that originally made torsemide the better choice. Which of the following correctly explains the pharmacokinetic rationale for switching back to furosemide?

• A) Furosemide is approximately 65% renally eliminated via tubular secretion through OAT, with minimal hepatic metabolism; while stage 3b CKD does increase OAT competition and can lower luminal furosemide concentration, the hepatic impairment from alcoholic hepatitis does not significantly affect furosemide's clearance pathway; torsemide's approximately 80% dependence on hepatic CYP2C9 metabolism is the factor that makes it unreliable when liver function is compromised; switching to furosemide at an appropriate IV dose — accepting the need for careful dose titration due to CKD-related OAT competition — provides a more predictable pharmacokinetic profile during the period of hepatic impairment
• B) Furosemide is preferable because it undergoes predominantly hepatic glucuronidation at a different enzyme (UGT1A9) than torsemide's CYP2C9 pathway; alcoholic hepatitis preferentially impairs CYP2C9 while sparing UGT1A9, making furosemide's hepatic metabolism resistant to the same impairment affecting torsemide; this enzyme-specific sparing means furosemide accumulates less than torsemide in alcoholic hepatitis at equivalent doses
• C) Furosemide is preferable because its shorter half-life of 1.5–2 hours means that any accumulation from hepatic impairment self-corrects within 4–6 hours of each dose; the rapid washout prevents the progressive accumulation seen with torsemide; the dose should be escalated by 50% during hepatic impairment to compensate for the reduced clearance, and continuous infusion is preferred to prevent the trough-peak fluctuations that cause rebound sodium retention
• D) Furosemide is preferable because, unlike torsemide, it does not require OAT-mediated secretion to reach the tubular lumen; furosemide crosses the proximal tubular cell by passive lipid diffusion from the peritubular capillary to the luminal surface of NKCC2 without any transporter; this transporter-independent delivery is unaffected by either CKD or hepatic impairment, making furosemide uniformly reliable across all degrees of both renal and hepatic dysfunction
• E) Furosemide is preferable because hepatic impairment in alcoholic hepatitis induces CYP3A4 through an alcohol-activated pregnane X receptor (PXR) mechanism; CYP3A4 induction accelerates torsemide metabolism paradoxically at low doses while inhibiting it at high doses; furosemide is not a CYP3A4 substrate and is therefore immune to the PXR-CYP3A4 axis that makes torsemide kinetics erratic in alcoholic liver disease

23. [CASE 6 — QUESTION 3] Continuing with the same patient. With potassium at 2.4 mEq/L and magnesium at 1.1 mg/dL, a repeat digoxin level is 0.92 ng/mL (previously 0.76 ng/mL on the same dose). The patient now develops nausea, anorexia, and a junctional rhythm with a heart rate of 42 bpm. The cardiology fellow notes that the digoxin level remains below 1.0 ng/mL and asks why clinical toxicity has developed. Which of the following best explains why this patient has digoxin toxicity at a digoxin level within the therapeutic range?

• A) The junctional bradycardia reflects hepatic accumulation of a digoxin metabolite produced by CYP3A4 in the setting of alcoholic hepatitis; the standard plasma digoxin assay measures parent drug only and does not detect the toxic metabolite; the metabolite has 5-fold greater vagotonic potency at the AV node than parent digoxin, producing AV block at plasma parent drug levels that appear therapeutic
• B) The digoxin level of 0.92 ng/mL is actually above the therapeutic range for heart failure rate control; current guidelines specify a therapeutic target of 0.5–0.7 ng/mL for HFrEF with atrial fibrillation; at 0.92 ng/mL, digoxin toxicity is expected and does not require an electrolyte explanation; the appropriate action is to hold digoxin and reduce the maintenance dose
• C) The junctional rhythm reflects torsemide-induced upregulation of cardiac NKCC1 channels that enhanced digoxin binding to the Na/K-ATPase; by inhibiting NKCC1 in cardiomyocytes, torsemide altered the membrane potential in a way that increased digoxin's affinity for the alpha-subunit; this pharmacokinetic-pharmacodynamic interaction resolves when torsemide is held, independent of any electrolyte abnormality
• D) The creatinine rise from 1.8 to 3.1 mg/dL during the over-diuresis episode reduced digoxin's renal clearance proportionally; digoxin is renally eliminated and its clearance tracks GFR; the 72% rise in creatinine (1.8 to 3.1) corresponds to approximately a 40% reduction in GFR and a 40% reduction in digoxin clearance, raising steady-state digoxin levels from 0.76 to 0.92 ng/mL through pharmacokinetic accumulation; this is sufficient to explain the toxicity without invoking electrolyte mechanisms
• E) Potassium and magnesium are physiological competitors of digoxin at the extracellular face of the Na/K-ATPase alpha-subunit; with potassium depleted to 2.4 mEq/L, the competitive antagonism that normally limits digoxin binding affinity is substantially reduced, and digoxin occupies a greater fraction of Na/K-ATPase molecules at the same plasma level of 0.92 ng/mL; simultaneously, hypomagnesemia (1.1 mg/dL) has depleted intracellular magnesium, removing the physiological ROMK channel block in collecting duct principal cells, producing obligatory potassium secretion that perpetuates and deepens the hypokalemia regardless of potassium supplementation; the conventional therapeutic range was validated at normal electrolyte concentrations and does not predict safety when both competing cations are simultaneously depleted; a digoxin level of 0.92 ng/mL in this electrolyte context represents pharmacodynamic over-inhibition of cardiac Na/K-ATPase sufficient to cause the observed conduction abnormality

24. [CASE 6 — QUESTION 4] Continuing with the same patient. Digoxin is held. The team must correct the electrolyte abnormalities (potassium 2.4 mEq/L, magnesium 1.1 mg/dL) and then reassess the digoxin situation. A pharmacology consultant is asked to specify the correct repletion sequence, the mechanistic justification for prioritizing one electrolyte, and the implications for digoxin management once electrolytes are normalized. Which of the following correctly integrates the repletion sequence with the digoxin pharmacodynamic rationale?

• A) Potassium should be repleted first because hypokalemia is the direct cause of enhanced digoxin binding at the Na/K-ATPase; restoring potassium to 4.0 mEq/L will immediately normalize competitive antagonism and reduce digoxin binding affinity; magnesium repletion is a secondary measure that can follow once potassium has stabilized; the digoxin dose should be permanently reduced by 50% because the liver disease has impaired hepatic digoxin metabolism, raising the true steady-state level above what the assay reflects
• B) Magnesium and potassium should be repleted simultaneously in equal quantities because the two deficits are independent and both must be corrected before either mechanism of digoxin sensitization resolves; the digoxin dose should be immediately doubled once electrolytes are corrected, as the current subtherapeutic ventricular rate during the junctional rhythm indicates under-dosing relative to the true therapeutic requirement
• C) Magnesium must be repleted first: depleted intracellular magnesium has removed the physiological ROMK channel block in collecting duct principal cells, producing constitutive potassium secretion that renders potassium replacement ineffective until magnesium is corrected; once magnesium is repleted and ROMK channels are re-blocked, potassium supplementation effectively raises serum potassium; restoring potassium then re-establishes competitive antagonism at the Na/K-ATPase alpha-subunit, reducing digoxin binding affinity and allowing the Na/K-ATPase inhibitory effect of 0.92 ng/mL digoxin to return to the level appropriate for that plasma concentration at normal electrolytes; digoxin can be restarted at the same dose once electrolytes are fully corrected, as the level of 0.92 ng/mL without electrolyte derangement is within the therapeutic range
• D) Neither magnesium nor potassium should be repleted before the junctional rhythm is pharmacologically reversed with atropine; atropine increases AV nodal conduction and restores sinus rhythm, eliminating the immediate hemodynamic risk; once sinus rhythm is restored, electrolyte repletion can proceed in any order since the cardiac toxicity has been eliminated; digoxin should be permanently discontinued because the patient has demonstrated life-threatening sensitivity at therapeutic levels
• E) Potassium should be repleted first because ROMK channel opening in this patient is driven by hypokalemia, not by magnesium depletion; when serum potassium falls below 3.0 mEq/L, a potassium-sensing mechanism on collecting duct principal cells activates ROMK constitutively; potassium repletion above 3.5 mEq/L closes this potassium-sensor-driven ROMK activation; magnesium can then be repleted as an independent step; digoxin should be restarted at 0.0625 mg daily (half the current dose) because hypokalemia has permanently upregulated Na/K-ATPase sensitivity